Macrophage cannibalism: efferocytosis in atherosclerosis.

IF 4.6 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current opinion in lipidology Pub Date : 2025-08-25 DOI:10.1097/MOL.0000000000001010

Amy A Baxter, Ivan K H Poon, Denuja Karunakaran

{"title":"Macrophage cannibalism: efferocytosis in atherosclerosis.","authors":"Amy A Baxter, Ivan K H Poon, Denuja Karunakaran","doi":"10.1097/MOL.0000000000001010","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review explores the evolving understanding of efferocytosis - the clearance of dead or dying cells by phagocytes - in the context of atherosclerosis. It highlights recent discovers in cell death modalities, impaired clearance mechanisms and emerging therapeutic strategies aimed at restoring efferocytosis to stabilize plaques and resolve inflammation.Recent findings: Recent studies have expanded the scope of efferocytosis beyond apoptotic cells to include other pro-inflammatory cell death modes, including pyroptosis, necroptosis and ferroptosis, revealing context-dependent clearance efficiency and immunological outcomes. Novel mechanisms of impaired efferocytosis have been identified, including CD47- or CD147-mediated inhibition, efferocyte metabolic reprogramming and age-related MerTK cleavage. Therapeutic advances include nanoparticle-mediated delivery of SHP-1 inhibitors, engineered efferocytotic receptors, and treatment with resolvin D1 to enhance efferocytosis and reduce inflammation.Summary: Efferocytosis is a critical process in maintaining vascular homeostasis and preventing plaque rupture in atherosclerosis. Its impairment contributes to necrotic core expansion and chronic inflammation. Advances in understanding the molecular regulation of efferocytosis and its therapeutic modulation offer new avenues for intervention. Targeting efferocytosis may complement lipid-lowering and/or anti-inflammatory therapies, representing a promising strategy for cardiovascular disease management.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOL.0000000000001010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review explores the evolving understanding of efferocytosis - the clearance of dead or dying cells by phagocytes - in the context of atherosclerosis. It highlights recent discovers in cell death modalities, impaired clearance mechanisms and emerging therapeutic strategies aimed at restoring efferocytosis to stabilize plaques and resolve inflammation.

Recent findings: Recent studies have expanded the scope of efferocytosis beyond apoptotic cells to include other pro-inflammatory cell death modes, including pyroptosis, necroptosis and ferroptosis, revealing context-dependent clearance efficiency and immunological outcomes. Novel mechanisms of impaired efferocytosis have been identified, including CD47- or CD147-mediated inhibition, efferocyte metabolic reprogramming and age-related MerTK cleavage. Therapeutic advances include nanoparticle-mediated delivery of SHP-1 inhibitors, engineered efferocytotic receptors, and treatment with resolvin D1 to enhance efferocytosis and reduce inflammation.

Summary: Efferocytosis is a critical process in maintaining vascular homeostasis and preventing plaque rupture in atherosclerosis. Its impairment contributes to necrotic core expansion and chronic inflammation. Advances in understanding the molecular regulation of efferocytosis and its therapeutic modulation offer new avenues for intervention. Targeting efferocytosis may complement lipid-lowering and/or anti-inflammatory therapies, representing a promising strategy for cardiovascular disease management.

查看原文本刊更多论文

巨噬细胞自相残杀：动脉粥样硬化中的efferocytosis。

综述目的：本文探讨了在动脉粥样硬化的背景下，对efferocytosis（吞噬细胞清除死亡或垂死细胞）的不断发展的理解。它强调了最近在细胞死亡模式、受损清除机制和旨在恢复efferocytosis以稳定斑块和解决炎症的新兴治疗策略方面的发现。最近的发现：最近的研究将efferocytosis的范围扩大到凋亡细胞之外，包括其他促炎细胞死亡模式，包括焦亡（pyroptosis）、坏死亡（necroptosis）和铁亡（ferroptosis），揭示了上下文依赖的清除效率和免疫结果。已经确定了受损的effocytosis的新机制，包括CD47或cd147介导的抑制，effocytocymetabolic reprogramming和年龄相关的MerTK切割。治疗进展包括纳米颗粒介导的SHP-1抑制剂递送、工程化的efferocytic受体和resolvin D1治疗以增强efferocytic和减少炎症。摘要：在动脉粥样硬化中，efferocysis是维持血管稳态和防止斑块破裂的关键过程。它的损伤导致坏死性核心扩张和慢性炎症。对effocytosis的分子调控及其治疗调节的理解的进展为干预提供了新的途径。靶向efferocytosis可以补充降脂和/或抗炎治疗，代表了心血管疾病管理的一个有前途的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in lipidology 医学-内分泌学与代谢

CiteScore

6.70

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.